Hot Topic: Learnings From Managing Immunogenicity Risks to Protein Based Therapeutics; Need to Pivot for Cell and Gene Therapies or 1 Size Fits All?

Hot Topic Moderator(s)

• 

  Amy Rosenberg, MD

  Senior Director of Immunology
  Epivax
  Providence, Rhode Island

Presentations:

• 3:30 PM – 3:45 PM ET

  Deimmunization and Immune Tolerance Strategies for Protein Therapeutics: Extension of Principles to Novel Therapeutic Modalities.
  

  Hot Topic Speaker: Anne De Groot, MD – EpiVax, Inc.
• 3:45 PM – 4:00 PM ET

  Preclinical and Clinical Immunogenicity Risk Mitigation and Management for CAR-T Therapies
  

  Hot Topic Speaker: Vibha Jawa, Ph.D., FAAPS – Bristol Myers Squibb
• 4:00 PM – 4:15 PM ET

  Enhancing Engraftment of Hematopoietic Stem Cells Using CD117-Saporin Immunotoxin: Advantages in Gene Therapy, Allotransplantation and Tolerance Induction
  

  Government Speaker: Philip Murphy, MD – NIAID, NIH
• 4:15 PM – 4:30 PM ET

  Panel Discussion
  

  Hot Topic Moderator: Amy S. Rosenberg, MD – Epivax

  Hot Topic Speaker: Anne De Groot, MD – EpiVax, Inc.

  Government Speaker: Philip Murphy, MD – NIAID, NIH

  Hot Topic Speaker: Vibha Jawa, Ph.D., FAAPS – Bristol Myers Squibb